Please try another search
Hua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with insulin for late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson’s disease; and Fructokinase Inhibitor for Metabolic disease. The company was incorporated in 2011 and is based in Beijing, China.
Name | Age | Since | Title |
---|---|---|---|
Robert Taylor Nelsen | 60 | 2010 | Non-Executive Chairman |
Li Chen | 59 | 2010 | Founder, CEO & Executive Director |
Yiu Leung Cheung | 64 | 2023 | Independent Non-Executive Director |
Yiu Wa Tsui | 74 | 2018 | Independent Non-Executive Director |
James S. MacDonald | - | - | Member of Scientific Advisory Board |
Chien Cheng Lin | 53 | 2017 | Executive VP, Chief Strategy Officer & Executive Director |
Bennett M. Shapiro | 84 | - | Member of Scientific Advisory Board |
Catherine D. Strader | 69 | - | Member of Scientific Advisory Board |
William Robert Keller | 76 | 2018 | Independent Non-executive Director |
Fangxin Li | 32 | 2023 | Non-Executive Director |
Yi Zhang | 49 | 2018 | Senior VP of Pharma Development, Chief Medical Officer – China and Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review